PLoS ONE (Jan 2020)

Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis.

  • Bernat Baeza-Raja,
  • Andrew Goodyear,
  • Xiao Liu,
  • Kevin Lam,
  • Lynn Yamamoto,
  • Yingwu Li,
  • G Steven Dodson,
  • Toshi Takeuchi,
  • Tatiana Kisseleva,
  • David A Brenner,
  • Karim Dabbagh

DOI
https://doi.org/10.1371/journal.pone.0234038
Journal volume & issue
Vol. 15, no. 6
p. e0234038

Abstract

Read online

Extracellular adenosine triphosphate (eATP) released by damaged cells, and its purinergic receptors, comprise a crucial signaling network after injury. Purinergic receptor P2X7 (P2RX7), a major driver of NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and IL-1β processing, has been shown to play a role in liver injury in murine diet- and chemically-induced liver injury models. It is unclear, however, whether P2RX7 plays a role in non-alcoholic steatohepatitis (NASH) and which cell type is the main target of P2RX7 pharmacological inhibition. Here, we report that P2RX7 is expressed by infiltrating monocytes and resident Kupffer cells in livers from NASH-affected individuals. Using primary isolated human cells, we demonstrate that P2RX7 expression in CD14+ monocytes and Kupffer cells primarily mediates IL-1β release. In addition, we show that pharmacological inhibition of P2RX7 in monocytes and Kupffer cells, blocks IL-1β release, reducing hepatocyte caspase 3/7 activity, IL-1β-mediated CCL2 and CCL5 chemokine gene expression and secretion, and hepatic stellate cell (HSC) procollagen secretion. Consequently, in a chemically-induced nonhuman primate model of liver fibrosis, treatment with a P2RX7 inhibitor improved histological characteristics of NASH, protecting from liver inflammation and fibrosis. Taken together, these findings underscore the critical role of P2RX7 in the pathogenesis of NASH and implicate P2RX7 as a promising therapeutic target for the management of this disease.